Buyers widening their own doors: demand already secured, far-side receiving constraint now being cleared
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO based on transcript. Need evaluate three conditions. Transcript: Surmodics. Key topics: Abbott SurVeil agreement, clinical trial TRANSCEND enrollment, product pipeline, Embolitech acquisition, etc. Question asks: Does management convey that company ALREADY HAS BUSINESS OR DEMAND SECURED/ARRIVING, but thing standing between company and meaningfully larger delivered business is counterparties' own ability to receive/install/qualify/stock/staff/certify/onboard/absorb it, and does management describe those counterparties as ALREADY WORKING ON that receiving-side preparation, with associated business mostly still ahead of reported results? Need parse. The company has agreements with Abbott for SurVeil. Revenue from Abbott is recognized based on costs/obligations. The constraint? The trial enrollment? Actually SurVeil revenue is tied to clinical trial progress. The "counterparty" Abbott? They have commercialization rights. But the thing standing between company and larger delivered business? The trial enrollment is company's own clinical trial? Not receiving-side absorption. The question specifically about counterparties' ability to receive, install, qualify, stock, staff, certify, onboard, absorb. In transcript, there is mention of "commercial agreements with several interested parties who are in the process of reviewing each of our products that have received regulatory approval." Also "Telemark microcatheter" undergoing clinical evaluation by interested parties. "We continue to have active and ongoing strategic in this product for multiple parties who are conducting their own clinical evaluation." "Our .014 PTA balloon catheter is also undergoing clinical evaluation both by Surmodics and interested parties." This sounds like potential partners are evaluating products. But is that "demand already in hand"? No, it's interest, evaluation, not secured orders. The question asks if management conveys that business is already in hand but counterparties need to absorb. Here it's more like potential partners evaluating, not yet signed. Also "commercial agreements with several interested parties who are in the process of reviewing" - that's negotiations, not secured. What about Abbott? The SurVeil agreement is already signed, revenue recognized.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
MKC · Q2 2018 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive, install, etc., and those counterpartie...**NO** The transcript describes a situation where McCormick has already won shelf-space changes and distribution improvements from retailers (customers have accepted the recommendations), but implementation is delayed due to retailers' own operational reset windows and competitor product sell-through. This is framed as a temporary, ongoing industry practice rather than a binding constraint being actively cleared right now to unlock a meaningfully larger volume of already-secured business. Management presents it as part of their category-management progress with runway ahead, not as counterparties clearing a receiving-side bottleneck that is already underway and will drive the bulk of the upside.
BIIB · Q2 2017 → YESThe question is about whether management conveys that they already have secured demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties are already ...YES The transcript shows management conveying exactly this situation for SPINRAZA. Demand is already secured and arriving: “significant uptake in the U.S.” with “strong demand across patient types” and “roughly two third of patients treated to date having Type 2 or Type 3 SMA.” The binding constraint is on 60% of Type 2 patients who have had spinal surgery, creating intrathecal administration challenges on the receiving side.
BXP · Q1 2022 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties ...YES The transcript shows management conveying secured demand through signed leases totaling over 975,000 square feet on vacant space that have not yet commenced occupancy, plus an additional 1.3 million square feet in active negotiations and over 750,000 square feet in the development pipeline.